Eli Lilly licenses preclinical antisense program designed to treat ALS, dementia

Eli Lilly added another neuroscience program to its pipeline, licensing an antisense oligonucleotide from the ALS biotech QurAlis.

The deal, announced Monday, is the latest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Immunotherapy during surgery? Surge Therapeutics nabs $32M to expand clinical plans after first dosing

Weeks ago, Surge Therapeutics marked what CEO Michael Goldberg hopes will go down in history as a turning point in cancer care: the first time

July 20, 2023

New statement highlights nurses’ role in managing psychosocial health after stroke

Nurses play a key role in helping patients manage emotional and social health challenges, or psychosocial health, after a stroke, and improved screening and assessment

August 19, 2024

FDA adds vaporized hydrogen peroxide as sterilization alternative to EtO

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration

January 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.